Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Saved in:
| Title: | Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. |
|---|---|
| Authors: | Klein-Brill A; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Amar-Farkash S; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Lawrence G; Anthem Innovation Israel, Ltd, Tel Aviv, Israel., Collisson EA; Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco., Aran D; Anthem Innovation Israel, Ltd, Tel Aviv, Israel.; Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.; The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel.; Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel. |
| Source: | JAMA network open [JAMA Netw Open] 2022 Jun 01; Vol. 5 (6), pp. e2216199. Date of Electronic Publication: 2022 Jun 01. |
| Publication Type: | Comparative Study; Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
